Health Economics and Data Analytics, School of Public Health, Faculty of Health Sciences, Curtin University, GPO Box U1987, Perth, Western Australia, 6845, Australia.
School of Medicine, College of Health & Medicine, University of Tasmania, Churchill Avenue, Hobart, Tasmania, 7005, Australia.
BMC Cancer. 2020 Jul 6;20(1):625. doi: 10.1186/s12885-020-07103-w.
Sarcomas are a heterogeneous group of malignancies arising from mesenchymal cells. Epidemiological studies on sarcoma from Australia are lacking, as previous studies have focused on a sarcoma type (e.g. soft tissue) or anatomical sites.
Linked cancer registry, hospital morbidity and death registration data were available for Western Australia (WA) from 1982 to 2016. All new sarcoma cases among WA residents were included to estimate incidence, prevalence, relative survival and cancer-related hospitalisation, using the Information Network on Rare Cancers (RARECARENet) definitions. To provide a reference point, comparisons were made with female breast, colorectal, prostate and lung cancers.
For 2012-16, the combined sarcoma crude annual incidence was 7.3 per 100,000, with the majority of these soft tissue sarcoma (STS, incidence of 5.9 per 100,000). The age-standardised incidence and prevalence of STS increased over time, while bone sarcoma remained more stable. Five-year relative survival for the period 2012-16 for STS was 65% for STS (higher than lung cancer, but lower than prostate, female breast and colorectal cancers), while five-year relative survival was 71% for bone sarcoma. Cancer-related hospitalisations cost an estimated $(Australian) 29.1 million over the study period.
STS incidence has increased over time in WA, with an increasing proportion of people diagnosed aged ≥65 years. The analysis of health service use showed sarcoma had a lower mean episode of cancer-related hospitalisation compared to the reference cancers in 2016, but the mean cost per prevalent person was higher for sarcoma than for female breast, colorectal and prostate cancers.
肉瘤是一种起源于间充质细胞的异质性恶性肿瘤。来自澳大利亚的肉瘤流行病学研究很少，因为以前的研究集中在一种肉瘤类型（例如软组织）或解剖部位。
从 1982 年到 2016 年，西澳大利亚州（WA）有可用的癌症登记处、医院发病率和死亡率登记处的链接数据。所有在 WA 居住的新肉瘤病例都被纳入进来，以根据罕见癌症信息网络（RARECARENet）的定义来估算发病率、患病率、相对生存率和癌症相关的住院治疗情况。为了提供一个参考点，与女性乳腺癌、结直肠癌、前列腺癌和肺癌进行了比较。
2012-16 年，合并的肉瘤粗年发病率为每 10 万人 7.3 例，其中大多数为软组织肉瘤（STS，发病率为每 10 万人 5.9 例）。STS 的年龄标准化发病率和患病率随着时间的推移而增加，而骨肉瘤则保持相对稳定。2012-16 年期间，STS 的 5 年相对生存率为 65%（高于肺癌，但低于前列腺癌、女性乳腺癌和结直肠癌），而骨肉瘤的 5 年相对生存率为 71%。该研究期间，癌症相关住院治疗的费用估计为 2910 万澳元。
在 WA，STS 的发病率随着时间的推移而增加，诊断年龄≥65 岁的人所占比例不断增加。对卫生服务利用情况的分析表明，2016 年，与参考癌症相比，肉瘤的癌症相关住院治疗平均发作次数较低，但每例现患病人的平均费用高于乳腺癌、结直肠癌和前列腺癌。
